Mountain Valley MD Shares 2024 Business Developments and Innovations
Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTCQB: MVMDF) is excited to announce a comprehensive business update, highlighting its progress in commercialization across three focal areas: nutraceuticals, agriculture, and husbandry technologies. This detailed report showcases the innovative strategies and technological advancements that MVMD has embraced in recent times.
Nutraceutical Innovations
The Company’s Quicksome™ technology is at the forefront of enhancing the administration and effectiveness of nutraceutical products. MVMD's patented liposomal technology involves proprietary formulations aimed at optimizing molecule delivery. The focus on delivering active ingredients in sublingual nutraceutical applications ensures enhanced efficacy, accurate dosing, and reduced variability.
Quicksome™ Technological Benefits
MVMD's Quicksome™ technology has illustrated notable advantages, particularly in manufacturing cost reduction, allowing products to utilize up to one-seventh the amount of a target molecule compared to traditional methods. This dose-sparing characteristic resonates with conscious consumers looking for quality and efficiency in their health and wellness products.
In pursuit of streamlining product development, MVMD has partnered with a leading U.S. manufacturer to produce nutraceutical products that embody its proprietary technologies. This collaboration has opened avenues for multiple formulation projects.
OUD Adjunct Therapy and Testosterone Product Development
One of the standout projects includes an opioid use disorder (OUD) adjunct therapy developed in conjunction with a U.S. biotech client. The sublingual tablet samples are poised for manufacturing, with the strategy focused on supporting upcoming clinical trials in the following years. The product aims to aid in reducing cravings and relapse rates in OUD patients.
Additionally, MVMD has formulated a novel fenugreek glycosides testosterone product leveraging Quicksome™ technology. This product is currently undergoing testing in human subjects to evaluate its impact on testosterone production, muscle mass, and overall vitality.
Agricultural Advances
MVMD continues its work in the agricultural sector, leveraging the licensed Agrarius agricultural plant signaling technology. The technology is designed to increase crop yields organically while minimizing fertilizer and pesticide usage, aligning with sustainable farming practices.
Commercialization Efforts and Market Expansion
Since entering an Amended and Restated Supply and License Agreement with Agrarius Corp., MVMD has made substantial progress in commercializing Agrarius within North America and other territories. The product has received market approvals in several countries and states, including Canada and parts of Europe, fostering growth opportunities in diverse agricultural markets.
The successful registration of Agrarius products allows MVMD to partner with significant agricultural brands to improve product performance across various crops. They are actively exploring new distributor agreements and scaling up product availability in regions such as Panama and Brazil.
Innovations in Husbandry
MVMD is also making waves in the husbandry sector through its Quicksol™ technology. The recent Soluvec™ 1% product formulation has gained traction in Bangladesh, facilitating distribution within the aquaculture industry.
Market Impacts and Future Prospects
Recent sales of Soluvec™ have demonstrated resilience following disruptions from climatic events. The software's evolving applications are expected to create broader opportunities in husbandry sectors, and the company plans to expand licensing to additional international markets. This progressive approach not only focuses on aquatic species but aims to diversify into broader husbandry applications.
Company Overview
Mountain Valley MD is committed to building a world-class organization centered around the strategic use of its proprietary technologies. The Company’s mission emphasizes the advanced delivery of health-enhancing molecules to promote well-being in both humans and animals.
With patented technologies, including Quicksome™ and Quicksol™, MVMD is poised to innovate across its sectors. The focus remains on improving product efficacy, enhancing agricultural resilience, and exploring new avenues for health-related advancements.
Frequently Asked Questions
What is Mountain Valley MD's primary focus for 2024?
Mountain Valley MD is focusing on advancing its commercialization strategies across nutraceuticals, agriculture, and husbandry technologies.
What technologies are highlighted in the business update?
The business update highlights Quicksome™ for nutraceuticals and Agrarius for agriculture, along with Quicksol™ for husbandry applications.
What are the anticipated outcomes for the opioid use disorder product?
The product aims to assist in reducing cravings and preventing relapses in patients undergoing treatment for opioid use disorder.
What expansion efforts are underway in agriculture?
MVMD is expanding its agricultural footprint through registered licenses to sell Agrarius products across multiple countries, enhancing crop yields sustainably.
How does MVMD's technology benefit animal husbandry?
MVMD's technology improves fish feed formulations, enhancing bioavailability and overall health in aquatic species, while also diversifying its applications to other husbandry areas.
